Abstract
Radioactive Iodine Treatment in Hyperthyroidism and Cancer Mortality—A Still Controversial Issue
Highlights
Hyperthyroidism is a severe condition of thyroid hormone excess.[1]
radioactive iodine (RAI) is the preferred first-line therapy for Graves disease (GD) in the United States and the United Kingdom because it is associated with a higher cure rate and lower relapse rate compared with antithyroid drugs (ATDs).[3]
In recent years, conflicting data have been published on the risk of malignant neoplasms in patients with hyperthyroidism following RAI.[4,5]
Summary
Hyperthyroidism is a severe condition of thyroid hormone excess.[1]. Graves disease (GD), toxic multinodular goiter, and toxic adenoma are the most common causes of hyperthyroidism in younger individuals living in areas with iodine sufficiency and in older individuals in iodine-deficient regions.[1]. In recent years, conflicting data have been published on the risk of malignant neoplasms in patients with hyperthyroidism following RAI.[4,5] hyperthyroidism itself has been associated with an increased risk of cancer, supporting a potential role of thyroid hormone excess on carcinogenicity.[6] In addition, an increased overall risk of cancer and greater cancer mortality has been reported with ATDs therapy when compared with RAI.[7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
